GHK-Cu

Topical GHK-Cu has small human studies across more than 20 years. Studies of creams and serums report fewer wrinkles and more collagen, including a 1-month biopsy pilot. Results are not uniform: a leg-ulcer trial and a post-laser study found no objective difference from their comparison. Injectable GHK-Cu has not been studied in human trials at all.

GHK-Cu is a naturally occurring three-amino-acid peptide that tightly binds copper, first isolated from human blood plasma in 1973 by Loren Pickart. Topical GHK-Cu is the evidence-supported route, with 20+ years of small human trials behind it; the injectable form has no human trial data at all.

GHK-Cu does two jobs at once: it signals, and it carries copper. As a signal, genomic work using the Broad Institute's Connectivity Map found it modulates expression of over 4,000 human genes, activating repair genes and suppressing genes tied to inflammation and tissue breakdown. That is an epigenetic effect rather than a surface one: it shifts the gene expression profile of aged cells toward patterns seen in younger tissue. As a carrier, it delivers copper to the enzyme lysyl oxidase, which cross-links collagen and elastin fibres into their functional, load-bearing form. Without copper, newly made collagen is structurally weak. It also directly stimulates fibroblasts to produce collagen types I and III, elastin and glycosaminoglycans, and coordinates the breakdown of damaged tissue with the deposition of properly organised replacement tissue rather than scar.

• Topical (evidence-supported)1–2 %

  Once daily · PM preferred, on clean slightly damp skin, before moisturiser

  The Playbook specifies a 1–2% serum or cream once daily; the anti-aging guide describes twice-daily application. Clinical studies showing benefit used concentrations from 0.01% upward. No cycling is needed for topical use.

• Injectable (limited evidence)1–2 mg

  Once daily

  Zero human trial data supports this route. Injectable GHK-Cu is not lawfully compoundable: it was placed in FDA Category 2 and came off that list in April 2026 only because the nomination was withdrawn, which is not permission. Never inject a topical skincare-grade product.

Not established in available literature. Use the calculator with the figures printed on your own vial.
Open the calculator

1. 1
   Week 1–4 (topical)

   Skin texture begins to smooth. Not visible yet: collagen gene activation takes time. Post-procedure healing after microneedling or laser is noticeably faster.

2. 2
   Week 4–8 (topical)

   First visible changes. Skin appears more hydrated and firmer, fine lines begin softening, tone becomes more even.

3. 3
   Week 8–12 (topical)

   Full results as measured in clinical trials: reduced wrinkle depth, increased skin density and thickness, improved elasticity.

4. 4
   Month 3+ (topical)

   Cumulative improvement. The longer it runs, the more collagen accumulates.

5. 5
   Week 1–2 (injectable)

   Wound healing effects appear earliest; reduced inflammation at injury sites.

6. 6
   Week 4–8 (injectable)

   Systemic effects reported: hair growth, joint recovery, skin quality. Note this route has no human trial support.

Absence from this list does NOT mean safety. It means lack of research.

Storage

Topical serums follow the manufacturer instructions. Lyophilized injectable powder: refrigerator 2–8°C, or freezer −20°C for long-term storage. Reconstituted with bacteriostatic water: refrigerate and discard after 28 days.

Cost

$30–$80 per month (1–2% serum, 30 mL)

1. 1
   Pickart et al., 2015 · GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration, BioMed Res Int

   Source
2. 2
   Pickart & Margolina, 2018 · Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data, Int J Mol Sci

   Source
3. 3
   Leyden et al., 2002 · Copper peptide facial cream clinical study (71 women, 12 weeks), AAD 60th Annual Meeting
4. 4
   Abdulghani et al., 1998 · Effects of topical creams containing vitamin C, a copper-binding peptide cream and melatonin compared with tretinoin on the ultrastructure of normal skin, Dis Manag Clin Outcomes 1(4)

   Source
5. 5
   Bishop et al., 1992 · A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers, J Vasc Surg 16(2)

   PMID 1495150
6. 6
   Miller et al., 2006 · Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin, Arch Facial Plast Surg 8(4)

   PMID 16847171
7. 7
   Siméon / Maquart et al., 1999 · Modulation of matrix metalloproteinases in wounds by GHK-Cu, J Invest Dermatol 112(6)

   PMID 10383745
8. 8
   Dou, Lee, Zhu et al., 2020 · The potential of GHK as an anti-aging peptide, Aging Pathobiol Ther 2(1)

   PMID 35083444Source
9. 9
   FDA · Meeting of the Pharmacy Compounding Advisory Committee, to be held before the end of February 2027, on cathelicidin LL-37, GHK-Cu, dihexa acetate, Melanotan II and PEG-MGF (content current as of 15 April 2026)

   Source